# @fixelinstitute on Facebook

- **Type:** Image
- **Original URL:** https://www.facebook.com/1275465578125102/posts/914262294245434
- **Gondola URL:** https://gondola.cc/posts/64720665-fixelinstitute-facebook
- **Thumbnail:** https://img.gondola.cc/tr:w-,h-,fo-auto/postThumbnails/ea7063e8c4.jpg
- **Posted:** 2025-01-15T22:00:58.000+00:00
- **Account Owner:** Grace Huff (@GraceHuff3) — https://gondola.cc/GraceHuff3

## Caption

Exploring Deutetrabenazine for Non-Dopa-Responsive Dystonia

🔵Objective: Assess the safety, tolerability, and efficacy of deutetrabenazine in adults with isolated dystonia.

🔵Key Results:
-40% of participants reached 48mg/day dose
-Common side effects: fatigue & diarrhea
-No significant changes in secondary safety measures
-MDS-UPDRS III scores worsened by ≥3 points in 46.7% of participants
-Improvements in symptoms for women with blepharospasm

🔵Conclusion: Deutetrabenazine shows promise for managing dystonia, particularly in blepharospasm cases.
#DystoniaResearch #Neurology #VMAT2Inhibition #MovementDisorders

## Stats

- **Views:** 0
- **Likes:** 2
- **Shares:** 1
- **Comments:** 0

## Tags

movementdisorders, vmat2inhibition, neurology, dystoniaresearch

---
Copyright (c) Gondola